Edit
SpyGlass Pharma, Inc.
https://www.spyglasspharma.com/Last activity: 06.06.2025
Probably Closed
SpyGlass Pharma was Co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman. The company is focused on the development of novel treatments for chronic ophthalmic diseases based on technology originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine.
Location: United States, California, Aliso Viejo
Employees: 11-50
Total raised: $165M
Founded date: 2019
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.06.2025 | Series D | $75M | - |
| 10.07.2023 | Series C | $90M | New Enterp... |
Mentions in press and media 11
| Date | Title | Description |
| 06.06.2025 | SpyGlass Pharma Secures $75 Million to Revolutionize Glaucoma Treatment | SpyGlass Pharma, a rising star in the ophthalmic biotechnology sector, has successfully closed a $75 million Series D funding round. This financial boost is a significant leap forward for the company, which is based in Aliso Viejo, Californ... |
| 05.06.2025 | SpyGlass Pharma: $75 Million Series D Raised For Advancing Drug Delivery Platform For Glaucoma Patients | SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. Sands Capital led the Series D funding round, which was joined by Gilde Healthcare and existing investors N... |
| 02.06.2025 | SpyGlass Pharma Scores $75 Million Series D Funding | ALISO VIEJO, CA, SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. >> Click here for more funding data on SpyGlass Pharma >> To export SpyGlass ... |
| 02.06.2025 | SpyGlass Pharma Raises $75M Series D Funding | SpyGlass Pharma, an Aliso Viejo, CA-based ophthalmic biotechnology company, raised $75M in Series D funding. The round was led by Sands Capital, joined by Gilde Healthcare and existing investors New Enterprise Associates (NEA), RA Capital, ... |
| 10.07.2023 | SpyGlass Pharma Closes $90M Series C Financing | SpyGlass Pharma, an Aliso Viejo, CA-based ophthalmic therapeutics company, raised $90M in Series C funding. The round was led by RA Capital Management alongside existing investors New Enterprise Associates and Vensana Capital, as well as ne... |
| 10.07.2023 | SpyGlass Pharma Scores $90M Series C | ALISO VIEJO, CA, SpyGlass Pharma, a company developing a treatment for glaucoma and other chronic ophthalmic diseases, announced a $90 million Series C funding round. >> Click here for more funding data on SpyGlass Pharma >>... |
| 10.07.2023 | SpyGlass Pharma Completes $90 Million Series C Financing to Advance Novel Treatments for Glaucoma and other Chronic Ophthalmic Diseases | www.spyglasspharma.com ALISO VIEJO, Calif. (PRWEB) July 10, 2023 SpyGlass Pharma, a privately-held ophthalmic therapeutics company, announced today closing $90 million in Series C financing. The financing, which was led by RA Capital Manage... |
| 15.09.2022 | SpyGlass Pharma to Unveil Innovative Drug Delivery Platform for Chronic Eye Conditions at Eyecelerator Prior to the American Academy of Ophthalmology Meeting | SpyGlass Pharma, Inc. ALISO VIEJO, Calif. (PRWEB) September 15, 2022 SpyGlass Pharma, a privately-held ophthalmic therapeutics company, today announced it will be unveiling a breakthrough drug delivery platform to treat chronic eye conditio... |
| 20.07.2021 | SpyGlass Pharma Appoints Industry Veteran Patrick Mooney as Chief Executive Officer | ALISO VIEJO, Calif. (PRWEB) July 20, 2021 SpyGlass Pharma (“SpyGlass”), a privately-held ophthalmic therapeutics company, has appointed industry veteran Patrick Mooney as Chief Executive Officer. This appointment coincides with broad compan... |
| - | SpyGlass Pharma: Ophthalmic Therapeutics Company Closes $90 Million | SpyGlass Pharma – a privately-held ophthalmic therapeutics company- recently announced the closing of $90 million in Series C financing. The financing, which RA Capital Management led alongside existing investors New Enterprise Associates (... |
Show more